정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1227 | Not yet recruiting | Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell) | COVID-19 | Biological: Experimental Group | Phase 4 | Sinovac Biotech Co., Ltd | INDUSTRY | 520 | All | 3 Years ~ 5 Years | Yangchun City Center for Disease Control and Prevention, Yangchun, Guangdong, China Zhanjiang Center for Diseases Control and Prevention, Zhenjiang, Guangdong, China |
| 1226 | Not yet recruiting | Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With Quadrivalent Influenza Vaccine And 23-valent Pneumococcal Polysaccharide Vaccine | COVID-19 | Biological: Experimental Group1 Biological: Experimental Group 2 Biological: Experimental Group 3 |
Phase 4 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 1320 | All | 18 Years | Huaiyin Center for Disease Control and Prevention, Huai'an, Jiangsu, China Binhai Center for Disease Control and Prevention, Yancheng, Jiangsu, China Xiangshui Center for Disease Control and Prevention, Yancheng, Jiangsu, China |
| 1225 | Recruiting | Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV | Vaccine | Biological: Coronavirus vaccine | Phase 4 | Beijing 302 Hospital | OTHER | 200 | All | 18 Years ~ 60 Years | The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China |
| 1224 | Not yet recruiting | Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) | Covid19 | Biological: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca) Biological: CoronaVac (Sinovac Biotech) Biological: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover) |
Phase 2 | D'Or Institute for Research and Education, Bill and Melinda Gates Foundation, Instituto Fernandes Figueira | OTHER | 520 | All | 18 Years | Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio De Grande Do Sul, Brazil Hospital Gloria D'or, Rio De Janeiro, Rio De, Brazil Centro de Estudos e Pesquisa em Molestias Infecciosas (CEPCLIN), Natal, Rio Grande Do Norte, Brazil |
| 1223 | Recruiting | Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells) | COVID-19 | Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56 |
Phase 2 | Jiangsu Province Centers for Disease Control and Prevention, Academy of Military Medical Sciences，Academy of Military Sciences，PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd | NETWORK | 480 | All | 18 Years ~ 85 Years | Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China |
| 1222 | Not yet recruiting | Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China | COVID-19 | Biological: Candidate Vaccine, SCB-2019 Other: Placebo |
Phase 2 | Zhejiang Clover Biopharmaceuticals, Inc. | INDUSTRY | 800 | All | 18 Years | Shanxi Center for Disease Control and prevention, Taiyuan, Shanxi, China Sichuan Center for disease control, Chengdu, Sichuan, China |
| 1221 | Recruiting | Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) | Covid19 | Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose) Biological: ChAdOx1-S not less than 2.5 × 10^8 infectious units |
Phase 3 | SK Bioscience Co., Ltd., International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations | INDUSTRY | 3990 | All | 18 Years | Korea University Ansan Hostpital, Ansan, Gyeonggi, Korea, Republic of Ajou university hospital, Suwon, Gyeonggi, Korea, Republic of Dong-A University Hospital, Busan, Korea, Republic of Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of Kyungpook National University Hospital, Daegu, Korea, Republic of Chonnam National University Hospital, Gwangju, Korea, Republic of Gachon University Gil Medical Center, Incheon, Korea, Republic of Inha university hospital, Incheon, Korea, Republic of Ewha womans university medical center, Seoul, Korea, Republic of Hallym university medical center, Seoul, Korea, Republic of Korea university Anam hospital, Seoul, Korea, Republic of Korea University Guro Hospital, Seoul, Korea, Republic of Severance Hospital, Seoul, Korea, Republic of Wonju severance christian hospital, Wonju, Korea, Republic of Trial site, Auckland, New Zealand Trial Site, Manila, Philippines Trial site, Quezon City, Philippines Trial site, Bangkok, Thailand Trial site, Chiang Mai, Thailand Trial site, Khon Kaen, Thailand Trial site, Dniprodzerzhyns'k, Dnipropetrovs'k, Ukraine Trial site, Dnipro, Ukraine Trial site, Kropyvnytskyi, Ukraine Trial site, Kyiv, Ukraine Trial site, Odesa, Ukraine Trial site, Hochiminh city, Vietnam |
